SynthesisInternational journal of molecular sciences2023
Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials.
Synthesis in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Pooled it
- Different Acupuncture Therapies for Postherpetic Neuralgia: An Overview of Systematic Reviews and Meta-analysis.Chinese journal of integrative medicine · 2025Pooled it
- Efficacy and safety of subcutaneous injection of botulinum toxin in the treatment of Chinese postherpetic neuralgia compared to analgesics: a systematic review of randomized controlled trials and meta-analysis.Frontiers in neurology · 2024Pooled it
- A comparison of the effectiveness of lacosamide and pregabalin in treating patients diagnosed with neuropathic pain: a randomized, controlled, open-label pilot trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Comparison of Duloxetine Supplemented With Pregabalin and Amitriptyline Supplemented With Pregabalin for the Treatment of Postherpetic Neuralgia: A Double-Blind, Randomized Crossover Trial.CNS neuroscience & therapeutics · 2025Trial
- Immunoinflammatory mechanisms and emerging therapies for postherpetic neuralgia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Postherpetic Neuralgia: Mechanisms, Risk Factors, and Stratified Management-A Narrative Review.CNS neuroscience & therapeutics · 2026Review
- Low-Level Light Therapy in Postherpetic Neuralgia: A Review of Mechanistic Insights and Clinical Implications.Cellular and molecular neurobiology · 2026Review
- The Hypothesis of Myelinodegeneration as an Initial Risk of Neuropathic Pain.Neuroscience bulletin · 2026Review
- Prescription Trends and Clinical Decision-Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross-Sectional Survey by the Spanish Pain Society.European journal of pain (London, England) · 2026Article
- Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention.MedComm · 2026Review
- [StagingZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Modified Transverse in-Plane Costotransverse Foramen Block for Thoracic Postherpetic Neuralgia: A Prospective Case Series.Journal of pain research · 2026Article
- Acupuncture for Postherpetic Neuralgia: An Evidence Mapping.Journal of pain research · 2026Review
- Article
- Efficacy and Safety of Cold Atmospheric Plasma-Assisted Therapy for Herpes Zoster: A Randomized, Parallel, Positive-Controlled, Non-inferiority Multicenter Clinical Trial.Dermatology and therapy · 2025Article
- Effects of Medical Ozone Injection via Intervertebral Foramen Epidural Space on Postherpetic Neuralgia: Protocol for a Randomized Controlled and Double-Blind Clinical Trial.JMIR research protocols · 2025Article
- Efficacy and Safety of Electroacupuncture for Postherpetic Neuralgia and Biomarker Evaluation: A Study Protocol for a Multicenter, Randomized Trial.Journal of pain research · 2025Article
- Construction of influencing factors and nomogram prediction model for post-herpetic neuralgia based on T cell function and inflammatory factors.Frontiers in medicine · 2025Article
- Effectiveness of High-Voltage, Long-Duration Pulsed Radiofrequency in the Treatment of Postherpetic Neuralgia in the Elderly: Protocol for a Randomized Clinical Trial.Journal of pain research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and there is a clinical need for new approaches. Several drugs under advanced clinical development are addressed in this review. A systematic literature search was conducted in three electronic databases (Medline, Web of Science, Scopus) and in the ClinicalTrials.gov register from 1 January 2016 to 1 June 2023 to identify Phase II, III and IV clinical trials evaluating drugs for the treatment of PHN. A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan), Voltage-Gated Calcium Channel (VGCC) α2δ subunit inhibition (crisugabalin, mirogabalin and pregabalin), Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1 (COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone) and Nerve Growth Factor (NGF) inhibition (fulranumab). In brief, there are several drugs in advanced clinical development for treating PHN with some of them reporting promising results. AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.